CMS Intravenous Histamine Therapy Coverage Policy: What Billing Teams Need to Know (NCD 21)

CMS updated National Coverage Determination (NCD) 21 on intravenous histamine therapy, with a modified policy effective March 12, 2026. The core position hasn't shifted — CMS maintains that histamine therapy is not covered as a Medicare benefit — but billing and revenue cycle teams should understand exactly what that means for claims and patient conversations. If your practice has received any inquiries about histamine therapy treatments, this policy makes the coverage boundary unambiguous.

What CMS NCD 21 Covers: The Only Accepted Uses of Histamine

Under NCD 21, the Centers for Medicare & Medicaid Services recognizes exactly one category of medically valid histamine use: diagnostic testing. The policy is explicit that histamine has scientifically valid clinical applications only when used to assess the following:

• The ability of the stomach to secrete acid — relevant in gastroenterology workups
• The integrity of peripheral sensory nerves, such as in leprosy evaluation
• Circulatory competency in limb extremities
• The presence of a pheochromocytoma — a rare adrenal gland tumor

These diagnostic applications fall under the Medicare benefit category of Physicians' Services. If a provider is using histamine as part of a legitimate diagnostic protocol for one of these four purposes, that service may be billable — but the claim must clearly support the diagnostic intent through documentation.

This is a narrow list. Anything outside these four indications finds no footing in Medicare coverage under this NCD.

What CMS Will Not Cover: Histamine Therapy in Any Form

The coverage denial in NCD 21 is sweeping. CMS states plainly that there is no scientifically valid clinical evidence that histamine therapy is effective for any condition — and this applies regardless of how the therapy is administered. Intravenous is named in the policy title, but the language covers all methods of administration.

CMS goes further: histamine therapy is neither accepted nor widely used by the medical profession. Under Medicare's reasonable and necessary standard (Section 1862(a)(1)(A) of the Social Security Act), a service must be reasonable and necessary for diagnosis or treatment of illness or injury. Histamine therapy fails that test, and CMS has said so on the record.

The practical implication is direct: claims submitted to Medicare for histamine therapy as a treatment will be denied. Attempting to submit such claims — particularly repeatedly after denials — creates compliance exposure, not just a revenue problem.

Why This Policy Matters in 2026: Functional and Integrative Medicine Context

This modified NCD matters in 2026 because histamine-related therapies have gained traction in functional medicine and direct-pay practice settings. Some providers are promoting intravenous histamine protocols for conditions ranging from chronic pain to immune dysfunction. Patients may ask whether Medicare covers these treatments — especially if they've heard about them through wellness communities or direct-to-consumer marketing.

Billing teams at practices that have even a marginal integrative medicine component should be alert to this. A patient arriving with a stack of supplements and a request for IV histamine therapy isn't an unusual scenario anymore. The answer, from a Medicare billing standpoint, is unambiguous: this is not a covered service.

Practices that offer ABN (Advance Beneficiary Notice of Noncoverage) workflows should be prepared to issue an ABN before providing any histamine therapy to Medicare beneficiaries. This protects the practice and informs the patient that they will bear financial responsibility for the service.

Affected Codes

The policy does not list specific CPT or HCPCS codes. CMS NCD 21 applies a categorical non-coverage determination to histamine therapy — meaning the denial is based on the service type itself rather than a code-specific exclusion.

Covered diagnostic applications: No specific codes are enumerated in the policy document. Providers billing for the four recognized diagnostic uses of histamine should use the most appropriate existing CPT codes that describe the diagnostic service performed, supported by documentation that reflects the specific diagnostic intent.

Non-covered services:

Related ICD-10 Diagnosis Codes: No specific ICD-10-CM codes are listed in NCD 21. Claims submitted for the covered diagnostic indications should carry diagnosis codes that directly reflect the clinical question being investigated — for example, codes for gastric acid disorders, peripheral neuropathy, or suspected pheochromocytoma — and should be chosen based on the individual patient's documented clinical presentation.

What Your Billing Team Should Do